Multaq (Dronedarone)

Dronedarone blocks multiple cardiac ion channels, including potassium, sodium and calcium currents, and also has anti‑adrenergic activity. By prolonging the cardiac action potential and stabilising repolarisation, it reduces the likelihood of abnormal atrial electrical activity, supporting a regular heart rhythm.

The dosage of Multaq is determined by the prescribing clinician based on the patient’s clinical condition, renal and hepatic function, and other medications. The prescriber will select the appropriate strength and dosing schedule in accordance with local prescribing guidelines.

Safety data for dronedarone in pregnancy and lactation are limited, and the product is generally not recommended for use in pregnant or nursing women. The potential risks to the fetus or infant should be weighed against the therapeutic benefit, and alternative treatments should be considered.

To request Multaq, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to dronedarone is amiodarone, another class III antiarrhythmic. Dronedarone generally has a shorter half‑life and fewer thyroid and pulmonary toxicities, but it may be less potent in some patients. Choice between the two depends on individual risk profiles, comorbidities and physician judgment.

Multaq tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect them from moisture, direct sunlight and excessive heat to maintain stability and potency throughout the shelf‑life.

Multaq is taken orally as a tablet, usually with food to improve absorption and reduce gastrointestinal discomfort. Patients should swallow the tablet whole with water and follow the dosing schedule prescribed by their healthcare provider.

Serious adverse events include liver injury, pulmonary toxicity, severe skin reactions such as Stevens‑Johnson syndrome, QT‑interval prolongation, and worsening heart failure. Patients should be monitored regularly for signs of these conditions, and therapy should be discontinued if they occur.

Multaq is contraindicated in patients with permanent atrial fibrillation, severe (NYHA class III/IV) heart failure, significant hepatic impairment, or known hypersensitivity to dronedarone. It should also be avoided in individuals taking strong CYP3A4 inhibitors or other drugs that may cause dangerous interactions.